RE:RE:RE:RE:Disapointed and mostly in the dark.Your personal expectations are not facts, based on those sortilin expression levels(facts) they now they can target cancers with best potential safety/efficacy results. The issue is posters like yourself with delusional and none significant expectations are disappointed so they are bailing out. They enrolled all comers so going forward they target most suitable (for their Sort1 technology)cancers that's the fact you seem not to grasp!
jfm1330 wrote: The phase Ia is at the worst case scenario level that is not a plain failure. I hate the study design mixing all kind of sortilin expression levels. They have data that we don't have, and it frustrates me. We are mostly in the dark about what is going on, except to now know that 300 mg/m2 is the best possible MTD we can expect. The problem, is that it is also the lowest possible significative MTD. I was expecting 420 mg/m2 as the minimal MTD. Now it's much lower than that. This is the main negative news we learned today.
jfm1330 wrote: SPCEO1 wrote: What changed today from your perspective and how did it lead you to be " mostly in the dark"?
As you have pointed out, and I agree, most everything positive for the stock depends upon a good result for the phase 1 trial. It looks like we will have to wait another 2-3 months to get the facts you are looking for.
jfm1330 wrote: I listen to the call. If you have a realistic and positive scenario based on facts, not wishful thinking, put it forward clearly because personally I don't see it. Again, no rose-colored glasses. I want something based on facts that would lead you to think that this stock will go up in the next year. Again, no wishful thinking. FACTS!!!